Other headlinesAccelaRAD extends client baseCarestream readies laser imager
MR maverick dodges Nasdaq bullet
Fonar has until Oct. 5 to prove to the Nasdaq exchange that the company has at least $500,000 in net income for the fiscal year ending June 30, 2009. The deadline was set by Nasdaq Listing and Hearing Review Council, which determined on June 24 that the maker of MR scanners can remain listed on the exchange until that time. Fonar has reported net income of more than $1 million for the first nine months of the current fiscal year.
AccelaRAD extends client base
IT network specialist AccelaRAD announced June 26 the installation of advanced digital management software at five new sites. Three are Mid-Atlantic Unified Health System-affiliated imaging centers, which are using AccelaRAD’s Virtual Radiology Network to provide PACS functionality, offsite archiving, and sophisticated online communication with referring physicians. The other two are using the network to provide remote access to images for offsite radiology reading groups.
Carestream readies laser imager
The FDA has cleared a tabletop laser imager from Carestream Health designed for digital mammography and general radiography. Shipments in the U.S. and other countries are set to begin immediately. The new laser imager, dubbed DRYVIEW 5850, offers 508 pixels-per-inch output. Two on-line film trays support DICOM printing of general radiography and mammography from both full-field digital and computed radiography systems.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Study Shows Enhanced Diagnosis of Coronary Artery Stenosis with Photon-Counting CTA
July 10th 2025In a new study comparing standard resolution and ultra-high resolution modes for patients undergoing coronary CTA with photon-counting detector CT, researchers found that segment-level sensitivity and accuracy rates for diagnosing coronary artery stenosis were consistently > 89.6 percent.
FDA Expands Approval of MRI-Guided Ultrasound Treatment for Patients with Parkinson’s Disease
July 9th 2025For patients with advanced Parkinson’s disease, the expanded FDA approval of the Exablate Neuro platform allows for the use of MRI-guided focused ultrasound in performing staged bilateral pallidothalamic tractotomy.